{"groups":[{"description":"Participants were randomized to receive treatment according to the local SOC chemotherapy (lurbinectedin, topotecan, or amrubicin \\[Japan only\\]) in 21-day cycles.","id":"FG000","title":"Standard of Care (SOC)"},{"description":"Participants were randomized to receive tarlatamab as an intravenous (IV) infusion: A step dose of 1 mg on Cycle 1 Day 1 followed by the target dose 10 mg on Cycle 1 Day 8, Cycle 1 Day 15, and every 2 weeks (Q2W) thereafter.","id":"FG001","title":"Tarlatamab 1 mg to 10 mg Q2W"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"111"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"102"},{"groupId":"FG001","numSubjects":"143"}],"type":"Ongoing in study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"255"},{"groupId":"FG001","numSubjects":"254"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"255"},{"groupId":"FG001","numSubjects":"254"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were randomized 1:1 to receive tarlatamab or standard of care (SOC) chemotherapy (lurbinectedin, topotecan , or amrubicin \\[Japan only\\]). Randomization was stratified by prior anti-programmed cell death 1 (PD-1) or prior anti-PD-Ligand (L)1 (yes/no), chemotherapy-free interval (≥180 days; \\<180 to ≥90 days; \\<90 days), presence of brain metastases (yes/no), and SOC (topotecan/amrubicin versus lurbinectedin).","recruitmentDetails":"Participants were enrolled at 166 centers in 30 countries worldwide starting from 31 May 2023. The primary analysis data is presented from the date of randomization up to the data cutoff date (DCO), 29 January 2025. The study is still ongoing."}